P., Riedel, J., Filbry, A., Warnke, K., Lofrano, C., Roggenkamp, D
Impurities, incorrect peptide sequences, or degraded stock significantly affect experimental outcomes
Zhong Z, Zhang C, Ni S, Ma M, Zhang X, Sang W, et al
Coskuns research contributions include: Preclinical characterization of GLP2s dual receptor agonism and pharmacological properties Elucidation of the complementary mechanisms by which GIP and GLP-1 receptor activation produce synergistic metabolic effects Investigation of GLP2s effects on glucose homeostasis, body weight regulation, and energy expenditure in animal models Development of the scientific rationale supporting GLP2s advancement into human clinical trials Publication of seminal research establishing GLP2s unique pharmacological profile as an imbalanced dual agonist His work has contributed significantly to advancing understanding of incretin biology and establishing GLP2 as the prototype for a new therapeutic class in metabolic disease treatment
